May 17, 2020

Sanofi appoints CFO of European automobile giant in surprise move

pharmaceutical
pharmaceutical
Catherine Sturman
2 min
 healthcare M&A’s (Getty Images)
Biopharmaceutical company Sanofi has recently appointed Jean-Baptiste Chasseloup de Chatillon as Executive Vice President, Chief Financial Officer (CFO...

Biopharmaceutical company Sanofi has recently appointed Jean-Baptiste Chasseloup de Chatillon as Executive Vice President, Chief Financial Officer (CFO) and Member of the Executive Committee, effective October 1st 2018.  

To ensure a smooth transition with Jérôme Contamine, the company’s current position holder, he will join the company in September. Contamine is set to retire after over nine years at the helm.

Serving as Chief Financial Officer and Executive Vice-President for PSA Group, Chasseloup de Chatillon has held a number of financial positions within Europe at the Group, bringing the business back from the brink in the last decade.

"Jean-Baptiste is an experienced CFO who has been part of the impressive turnaround of PSA Group,” stated Olivier Brandicourt, Chief Executive Officer at Sanofi.

See also

“His track record of successfully driving finance across different businesses and geographies throughout his career will be of great value to lead our very experienced team around the world.

"I would like to express my thanks and gratitude to Jerome Contamine for his excellent service to Sanofi during the company's transformation over the past decade. He has been a highly committed and trusted business partner to me and to my executive team."

Sanofi is continuing to go through a significant restructure. From acquiring Bioverativ for $11.6bn in early 2018 in order to maintain its position within the haemophilia and blood disorder sector, its decision to purchase Ablynx further compliments the business and will advance its R&D strategy.

Chasseloup de Chatillon is set to join the industry when it is facing significant change. From increased pressures on all sides, to the emergence of escalating healthcare costs, particularly within the pharmaceutical space, he will aim to replicate previous successes by tackling such a complex sector.

Share article

May 19, 2021

Vaccine rollout spurring dark net activity, McAfee finds

covid-19vaccine
darknet
covid-19
Fraud
2 min
Research by McAfee has found illegal sales of fake COVID-19 vaccines and tests on the dark net

A report by security software company McAfee has found a huge rise in the availability and demand for illegal COVID-19 vaccines. 

The research by McAfee Advanced Threat Research found evidence that COVID-19 vaccines are currently available on at least a dozen dark net marketplaces. Vaccines allegedly made by Pfizer-BioNTech are being sold for $600 to $2,500 per dose, with vendors using channels such as Wickr, Telegram, WhatsApp and Gmail to advertise and communicate. 

Some of the supposed vaccines are imported from the US, while others are packed in the UK and shipped all over the world, according to the listings.

Moderna vaccines, potentially fraudulent antibody tests and fake vaccine cards are also being increasingly sold on the dark web, on at least 10 different underground markets. 

Anne An, senior security researcher at McAfee’s Advanced Programs Group, told us that with the increased global demand for COVID-19 vaccinations, the demand for illegal vaccines, fake test results and vaccination record cards has also grown. "Consumers who are buying these items pose a serious threat to public health and spur the underground economy" she said. 

"Opportunistic cybercriminals capitalise on public interest in obtaining a COVID-19 immunity passport. These bad actors can also benefit by reselling the names, dates of birth, home addresses, contact details and other personally indefinable information of their customers." 

As well as cyber security measures, An says education is necessary to stem the rise in these illegal sales. "Dark net selling of illegal COVID-19 vaccinations, fake test results and vaccination record cards is both a cybersecurity issue and an educational issue.

"On the one hand, channels being used as a means of business have the responsibility to monitor and mitigate cybercriminal activity on their platforms. On the other, the ongoing efforts of government and medical officials to provide factual information on COVID-19 and vaccinations is critical to discouraging the demand for fraudulent alternatives."  

Read McAfee's report Fool’s Gold”: Questionable Vaccines, Bogus Results, and Forged Cards

Share article